Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids

Inclusion Criteria

• •1. Age 18 to 75 years
• •2. Documented physician-diagnosed asthma for at least 12 months prior to enrolment (v1)
• •3. Documented treatment with an asthma controller regimen requiring treatment with ICS (minimum dose of ≥ 250 ug fluticasone propionate via dry powder inhaler equivalents total daily dose) alone or in combination ≥ 6 months and that has been taken at a stable dose for at least 1 month prior to enrolment (v1)
• •4. Additional maintenance asthma controller medications must be given at a stable dose for at least 1 month prior to v1.
• •5. At enrolment (v1) the subject must have a predicted normal value (PNV) for the pre-bronchodilator (BD) FEV1\>50% and more than 1L.
• •6. Post-BD reversibility in FEV1 of ≥12% and ≥200 mL at enrolment (v1).